<!DOCTYPE html>
<html>
  <head>
    <meta charset="UTF-8">
    <title>Scenario 1: Reasonable Best-Case</title>
    <link type="text/css" rel="stylesheet" href="css/book.css" />
    <link type="text/css" rel="stylesheet" href="css/springer.css" />
  </head>
  <body class="book-chapter">
    <div class="article-part article-title" id="_7_0">Scenario 1: Reasonable Best-Case</div>
    <div class="article-part article-richtext article-body">
      <p></p>
      <table id="T21025241" class="table-100 table-center table-fixed" data-width="100" data-aligned="center" data-layout="fixed" data-category="none">
        <tbody>
          <tr>
            <td>
              <p>Transmissibility </p>
            </td>
            <td>
              <p>Immune escape </p>
            </td>
            <td>
              <p>Intrinsic severity</p>
            </td>
            <td>
              <p>Realised severity</p>
            </td>
          </tr>
          <tr>
            <td>
              <p>Orange</p>
            </td>
            <td>
              <p>Green</p>
            </td>
            <td>
              <p>Orange</p>
            </td>
            <td>
              <p>Green</p>
            </td>
          </tr>
        </tbody>
      </table>
      <p></p>
      <p>Narrative: Further variants emerge but there is no major antigenic evolution, gains in transmissibility or a return to Delta-level intrinsic severity. Minimal further escape from current vaccines and infection-induced immunity. Minor seasonal/regional outbreaks from waning immunity and minor antigenic change. Existing vaccines used annually to boost vulnerable only. Antivirals have a significant impact on mortality and morbidity and remain effective. Years with higher SARS-CoV-2 waves tend to have fewer influenza cases. In the next 12-18 months: Relatively small resurgence in Autumn/Winter 2022/23 with low levels of severe disease.</p>
    </div>
    <section class="fnlist" role="doc-footnotes"></section>
  </body>
</html>